Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD of Coya Therapeutics, Inc. from 2022 to Q2 2025
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Coya Therapeutics, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and change rate from 2022 to Q2 2025.
- Coya Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending June 30, 2025 was -$6.09M, a 111% decline year-over-year.
- Coya Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was -$15.6M, a 115% decline from 2023.
- Coya Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -$7.26M, a 40.7% increase from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)